Manhasset, New York – (work wire) – Since 2016, scientists in Feinstein Institutes for Medical Research They studied the genetic and cellular makeup of menstrual blood or menstrual water (ME) to diagnose endometriosis. Today they published a new study in Springer Nature Medicine BMC It shows their ability to use ME to identify patients who may have endometriosis.
Endometriosis occurs when uterine-like tissue grows outside the uterus and forms lesions. This condition affects 1 in 10 females of childbearing age, resulting in chronic and often debilitating pain or infertility and other medical complications. Because of the lack of non-surgical diagnostic tools, it can take seven to ten years to diagnose endometriosis. Currently, laparoscopic surgery is the only diagnostic method.
Led search Peter Gregersen, MDAnd the Kristen Metz, Ph.D., They analyzed genetic and cellular differences in healthy controls versus endometriotic subjects to find common biomarkers that could lead to new diagnostic approaches and potential treatments. Building on more than seven years of research, the new study is published in Medicine BMC Outlines the first use of single-cell RNA sequencing (scRNA-Seq) to compare endometrial tissue in ME freshly collected from 33 study participants.
Dr. said. Metz, Professor at Institute of Molecular Medicine at the Feinstein Institutes and co-director of Research OutSmarts Endometriosis (ROSE) study. “This new paper describes the potential of a new screening tool to identify endometriosis early and enable patients to get the help they need.”
The first published study showed that the characteristics of endometrial tissue shedding in ME differed in patients with endometriosis compared to (healthy) patients. When combined with clinical symptoms, there is a potential for ME to be used to screen or diagnose adolescent girls and women who may have symptoms of endometriosis.
“The ROSE study research helps us understand the molecular and genetic makeup of endometrial tissue in the Middle East from women with endometriosis,” said Dr. Gregersen, professor in the Institute of Molecular Medicine at the Feinstein Institutes and co-director of ROSE. “More than 2,000 women have participated in the ROSE study so far and we are grateful to them for helping us produce knowledge that will improve patients’ lives.”
In order to further validate these findings, the team recently started a new clinical trial to compare ME from asymptomatic women who have not been diagnosed but will undergo necessary surgery as part of their standard care to determine if they have the condition. Studies are also underway to investigate ME in symptomatic and asymptomatic adolescent girls for predicting endometriosis at ages and early stages.
“While endometriosis is a common condition, there is still a lack of diagnosis and appropriate early intervention,” she said. Kevin J. Tracy, MDPresident and CEO of the Feinstein Institutes. “These important findings from Dr. Gregersen and Metz promise to change our understanding of this disease and focus on improving the diagnosis and care they need.”
About the Feinstein Institutes
Feinstein Institutes for Medical Research It is the home of the Research Institutes of Northwell Health, the largest healthcare provider and private employer in New York State. With 50 research laboratories, 3,000 clinical research studies, and 5,000 researchers and staff, the Feinstein Institutes raise the bar for medical innovation through its five Institutes for Behavioral Sciences, Bioelectronics, Cancer, Health System Sciences, and Molecular Medicine. We are making breakthroughs in genetics, oncology, brain research, mental health, and autoimmunity, and we are a global scientific leader in bioelectronic medicine – a new scientific field with the potential to revolutionize medicine. For more information on how we produce knowledge to treat disease, visit http://feinstein.northwell.edu and follow us LinkedIn.